John L. Lamattina - 22 Dec 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
/s/ Andrew Reardon, Attorney-in-Fact for John L. LaMattina
Issuer symbol
LGND
Transactions as of
22 Dec 2022
Net transactions value
$0
Form type
4
Filing time
27 Dec 2022, 17:28:25 UTC
Previous filing
21 Jun 2022
Next filing
17 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Award $0 +4,484 $0.000000 4,484 22 Dec 2022 Common Stock 4,484 $67.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to reporting person of stock options that will vest and become exercisable on December 22, 2023.

Remarks:

Exhibit 24 - Power of Attorney.